Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infection

Aye Mya Sithu Shein, Dhammika Leshan Wannigama, Cameron Hurst, Peter N. Monk, Mohan Amarasiri, Vishnu Nayak Badavath, Phatthranit Phattharapornjaroen, William Graham Fox Ditcham, Puey Ounjai, Thammakorn Saethang, Naphat Chantaravisoot, Wanwara Thuptimdang, Sirirat Luk-in, Sumanee Nilgate, Ubolrat Rirerm, Chanikan Tanasatitchai, Naris Kueakulpattana, Matchima Laowansiri, Tingting Liao, Rosalyn KupwiwatRojrit Rojanathanes, Natharin Ngamwongsatit, Arsa Thammahong, Hitoshi Ishikawa, Daniel Pletzer, Asada Leelahavanichkul, Naveen Kumar Devanga Ragupathi, Pattama Wapeesittipan, S. M. Ali Hosseini Rad, Talerngsak Kanjanabuch, Robin James Storer, Kazuhiko Miyanaga, Longzhu Cui, Hiroshi Hamamoto, Paul G. Higgins, Anthony Kicic, Tanittha Chatsuwan, Parichart Hongsing, Shuichi Abe

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infection'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science